Search Results - "Gauler, T."

Long-term results of definitive radiochemotherapy in locally advanced cancers of the cervical esophagus by Gkika, E., Gauler, T., Eberhardt, W., Stahl, M., Stuschke, M., Pöttgen, C.

“…Summary The aim of this study was to retrospectively analyze the long‐term effectiveness of combined chemoradiation as the definitive treatment of locally…”
Get full text

EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104 by Boeck, S, Jung, A, Laubender, R P, Neumann, J, Egg, R, Goritschan, C, Vehling-Kaiser, U, Winkelmann, C, Fischer von Weikersthal, L, Clemens, M R, Gauler, T C, Märten, A, Klein, S, Kojouharoff, G, Barner, M, Geissler, M, Greten, T F, Mansmann, U, Kirchner, T, Heinemann, V

“…Background: We aimed to identify molecular epidermal growth factor receptor (EGFR) tissue biomarkers in pancreatic cancer (PC) patients treated with the…”
Get full text

A German multicenter, randomized phase III trial comparing irinotecan–carboplatin with etoposide–carboplatin as first-line therapy for extensive-disease small-cell lung cancer by Schmittel, A., Sebastian, M., Fischer von Weikersthal, L., Martus, P., Gauler, T.C., Kaufmann, C., Hortig, P., Fischer, J.R., Link, H., Binder, D., Fischer, B., Caca, K., Eberhardt, W.E.E., Keilholz, U.

“…This trial was designed to prove superiority of irinotecan over etoposide combined with carboplatin in extensive-disease small-cell lung cancer. Patients were…”
Get full text

Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer by Cohen, E.E.W., Licitra, L.F., Burtness, B., Fayette, J., Gauler, T., Clement, P.M., Grau, J.J., del Campo, J.M., Mailliez, A., Haddad, R.I., Vermorken, J.B., Tahara, M., Guigay, J., Geoffrois, L., Merlano, M.C., Dupuis, N., Krämer, N., Cong, X.J., Gibson, N., Solca, F., Ehrnrooth, E., Machiels, J.-P.H.

“…In the phase III LUX-Head & Neck 1 (LUX-H&N1) trial, second-line afatinib significantly improved progression-free survival (PFS) versus methotrexate in…”
Get full text

Prospects for online adaptive radiation therapy (ART) for head and neck cancer by Guberina, Maja, Guberina, Nika, Hoffmann, C, Gogishvili, A, Freisleben, F, Herz, A, Hlouschek, J, Gauler, T, Lang, S, Stähr, K, Höing, B, Pöttgen, C, Indenkämpen, F, Santiago, A, Khouya, A, Mattheis, S, Stuschke, M

“…The aim of the present study is to examine the impact of kV-CBCT-based online adaptive radiation therapy (ART) on dosimetric parameters in comparison to…”
Get full text

Heart dose exposure as prognostic marker after radiotherapy for resectable stage IIIA/B non-small-cell lung cancer: secondary analysis of a randomized trial by Guberina, M., Eberhardt, W., Stuschke, M., Gauler, T., Heinzelmann, F., Cheufou, D., Kimmich, M., Friedel, G., Schmidberger, H., Darwiche, K., Jendrossek, V., Schuler, M., Stamatis, G., Pöttgen, C.

“…Heart exposure to ionizing irradiation can cause ischaemic heart disease. The partial heart volume receiving ≥5Gy (heartV5) was supposed to be an independent…”
Get full text

Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC) by Joerger, M., von Pawel, J., Kraff, S., Fischer, J.R., Eberhardt, W., Gauler, T.C., Mueller, L., Reinmuth, N., Reck, M., Kimmich, M., Mayer, F., Kopp, H.-G., Behringer, D.M., Ko, Y.-D., Hilger, R.A., Roessler, M., Kloft, C., Henrich, A., Moritz, B., Miller, M.C., Salamone, S.J., Jaehde, U.

“…Variable chemotherapy exposure may cause toxicity or lack of efficacy. This study was initiated to validate pharmacokinetically (PK)-guided paclitaxel dosing…”
Get full text

Cetuximab, fluorouracil and cisplatin with or without docetaxel for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CeFCiD): an open-label phase II randomised trial (AIO/IAG-KHT trial 1108) by Klinghammer, K., Gauler, T., Dietz, A., Grünwald, V., Stöhlmacher, J., Knipping, S., Schroeder, M., Guntinas-Lichius, O., Frickhofen, N., Lindeman, H.-W., Fietkau, R., Haxel, B., Große-Thie, C., Maschmeyer, G., Zipfel, M., Martus, P., Knoedler, M., Keilholz, U.

“…The combination of cisplatin, 5-fluorouracil (5-FU) and cetuximab (PFC) is the reference first-line treatment for recurrent/metastatic (R/M) squamous cell…”
Get full text

Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part) by Vermorken, J.B., Peyrade, F., Krauss, J., Mesía, R., Remenar, E., Gauler, T.C., Keilholz, U., Delord, J.P., Schafhausen, P., Erfán, J., Brümmendorf, T.H., Iglesias, L., Bethe, U., Hicking, C., Clement, P.M.

“…Recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M-SCCHN) overexpresses &agr;v&bgr;5 integrin. Cilengitide selectively inhibits…”
Get full text

Systemic therapy in metastatic renal cell carcinoma (mRCC): an evidence-based recommendation of the German interdisciplinary RCC guidelines group by Grünwald, V., Bergmann, L., Brehmer, B., Eberhardt, B., Kastrati, Karin, Gauler, T., Gehbauer, G., Gschwend, J., Johannsen, M., Klotz, T., Protzel, C., Schenck, M., Staehler, M.

“…Purpose The treatment landscape in metastatic renal cell carcinoma (mRCC) has evolved dramatically in recent years. Within the German guideline committee for…”
Get full text

Dose-escalated radiotherapy with PET/CT based treatment planning in combination with induction and concurrent chemotherapy in locally advanced (uT3/T4) squamous cell cancer of the esophagus: mature results of a phase I/II trial by Pöttgen, C, Gkika, E, Stahl, M, Abu Jawad, J, Gauler, T, Kasper, S, Trarbach, T, Herrmann, K, Lehmann, N, Jöckel, K-H, Lax, H, Stuschke, M

“…This prospective phase I/II trial assessed feasibility and efficacy of dose-escalated definitive chemoradiation after induction chemotherapy in locally…”
Get full text

Respiration-controlled radiotherapy in lung cancer: Systematic evaluation of the optimal application practice by Guberina, M., Santiago, A., Pöttgen, C., Indenkämpen, F., Lübcke, W., Qamhiyeh, S., Gauler, T., Hoffmann, C., Guberina, N., Stuschke, M.

“…•The benefit of deep inspiration-breath-hold (DIBH) in radiotherapy is demonstrated in a reduced mean lung dose, mean heart dose and lungV20 in comparison to…”
Get full text

Efficacy and safety of biweekly i.v. administrations of the Aurora kinase inhibitor danusertib hydrochloride in independent cohorts of patients with advanced or metastatic breast, ovarian, colorectal, pancreatic, small-cell and non-small-cell lung cancer: a multi-tumour, multi-institutional phase II study by Schöffski, P., Besse, B., Gauler, T., de Jonge, M.J.A., Scambia, G., Santoro, A., Davite, C., Jannuzzo, M.G., Petroccione, A., Delord, J.-P.

“…According to the results of this multi-tumour, multi-institutional Simon two-stage design phase II study the aurora kinase inhibitor danusertib was found to…”
Get full text

TEMHEAD: a single-arm multicentre phase II study of temsirolimus in platin- and cetuximab refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) of the German SCCHN Group (AIO) by Grünwald, V., Keilholz, U., Boehm, A., Guntinas-Lichius, O., Hennemann, B., Schmoll, H.J., Ivanyi, P., Abbas, M., Lehmann, U., Koch, A., Karch, A., Zörner, A., Gauler, T.C.

“…Temsirolimus showed clinical efficacy in refractory squamous cell carcinoma of the head and neck (SCCHN), who failed platinum and epidermal growth factor…”
Get full text

A proof of concept trial of the anti-EGFR antibody mixture Sym004 in patients with squamous cell carcinoma of the head and neck by Machiels, J.-P., Specenier, P., Krauß, J., Dietz, A., Kaminsky, M.-C., Lalami, Y., Henke, M., Keilholz, U., Knecht, R., Skartved, N. J., Horak, I. D., Pamperin, P., Braun, S., Gauler, T. C.

“…Purpose The purpose of the trial was to assess the efficacy and tolerability of Sym004, a novel 1:1 mixture of two chimeric monoclonal antibodies (992 and…”
Get full text

Phase II study of pemetrexed in combination with cisplatin and cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck by Vermorken, J.B, Licitra, L, Stöhlmacher-Williams, J, Dietz, A, Lopez-Picazo, J.M, Hamid, O, Hossain, A.M, Chang, S.-C, Gauler, T.C

“…Abstract Purpose Platinum/5-fluorouracil plus cetuximab is a standard systemic treatment for recurrent or metastatic squamous cell carcinoma of the head and…”
Get full text

Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial by Clement, P.M., Gauler, T., Machiels, J.P., Haddad, R.I., Fayette, J., Licitra, L.F., Tahara, M., Cohen, E.E.W., Cupissol, D., Grau, J.J., Guigay, J., Caponigro, F., de Castro, G., de Souza Viana, L., Keilholz, U., del Campo, J.M., Cong, X.J., Ehrnrooth, E., Vermorken, J.B.

“…In the phase III LUX-Head & Neck 1 (LHN1) trial, afatinib significantly improved progression-free survival (PFS) versus methotrexate in recurrent and/or…”
Get full text

Formation and repair kinetics of Pt-(GpG) DNA adducts in extracted circulating tumour cells and response to platinum treatment by Nel, I, Gauler, T C, Eberhardt, W E, Nickel, A-C, Schuler, M, Thomale, J, Hoffmann, A-C

“…Background: Pt-(GpG) intrastrand crosslinks are the major DNA adducts induced by platinum-based anticancer drugs. In the cell lines and mouse models, the…”
Get full text

βV-tubulin expression is associated with outcome following taxane-based chemotherapy in non-small cell lung cancer by Christoph, D C, Kasper, S, Gauler, T C, Loesch, C, Engelhard, M, Theegarten, D, Poettgen, C, Hepp, R, Peglow, A, Loewendick, H, Welter, S, Stamatis, G, Hirsch, F R, Schuler, M, Eberhardt, W E E, Wohlschlaeger, J

“…Background: Tubulin-binding agents (TBAs) are effective in non-small cell lung cancer (NSCLC) treatment. Both β III- and β V-tubulins are expressed by cancer…”
Get full text

HIGH RATE OF METABOLIC COMPLETE RESPONSE AFTER LOW DOSE RADIOTHERAPY AND OBINUTUZUMAB IN EARLY STAGE FOLLICULAR LYMPHOMA: INITIAL RESULTS OF THE GAZAI STUDY (GLA 2018‐3) by Herfarth, K., Scholz, C. W., Hübel, K., Wirths, S., Buske, C., Dürig, J., Forstpointner, R., Heidegger, S., Lenz, G., König, L., Meißner, J., Höller, U., Baues, C., De‐Colle, C., Wiegel, T., Gauler, T., Li, M., Combs, S. E., Eich, H., Sander, A., Mavriopuoluo, E., Kieser, M., Pott, C., Dreyling, M.

Get full text